The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
89bio Appoints Teresa Perney As Chief Regulatory and Quality Officer
PRIVATESep 17, 2024•almost 2 years ago
Position
Chief Executive Officer
Company
89bio
Rohan Palekar
San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
89bio, Inc announced the appointment of Teresa Perney, PhD as Chief Regulatory and Quality Officer, effective today. Dr Perney brings extensive expertise in regulatory affairs, product development, and quality assurance to the company.
Company Information
Company
89bio
Location
San Francisco, California, United States
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG.
San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma